Compare BOSC & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | RLYB |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5M | 28.7M |
| IPO Year | 2002 | 2021 |
| Metric | BOSC | RLYB |
|---|---|---|
| Price | $4.78 | $10.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 48.3K | ★ 235.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $600,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.30 | $0.22 |
| 52 Week High | $6.72 | $11.49 |
| Indicator | BOSC | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 51.49 | 91.42 |
| Support Level | $4.80 | $0.48 |
| Resistance Level | $5.07 | N/A |
| Average True Range (ATR) | 0.18 | 0.79 |
| MACD | 0.02 | 0.41 |
| Stochastic Oscillator | 49.11 | 91.99 |
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.